On 14 October 2016, orphan designation (EU/3/16/1752) was granted by the European Commission to Pfizer Limited, United Kingdom, for human monoclonal IgG1 antibody against tissue factor pathway (also known as PF-06741086) for the treatment of haemophilia A.
The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in November 2018.
Human monoclonal IgG1 antibody against tissue factor pathway inhibitor
|Disease / condition||
Treatment of haemophilia A
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;